Table 5 PROMIS scores differences between MACE and non-MACE.

From: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial

PROMIS 10

Total(n = 469)

MACE (n = 58)

Non-MACE (n = 411)

P value

GPH

 Baseline

43.83 ± 4.97

44.11 ± 4.98

43.79 ± 4.97

0.648

 Week 12

48.46 ± 6.91

47.47 ± 6.19

48.59 ± 7.00

0.231

 Week 48

52.35 ± 6.41

51.16 ± 7.09

52.50 ± 6.31

0.144

GMH

 Baseline

46.25 ± 6.15

47.03 ± 6.15

46.14 ± 6.15

0.294

 Week 12

50.64 ± 7.67

50.58 ± 7.79

50.65 ± 7.66

0.946

 Week 48

54.13 ± 8.12

52.09 ± 8.40

54.40 ± 8.06

0.048

Back to article page